Cash Runway Screener
In Development — Get NotifiedBiotech companies sorted by cash runway. Identify dilution risk before offerings hit. Derived from latest 10-Q filings. Why cash runway matters →
How cash runway screening works
What is biotech cash runway?
Cash runway is the number of quarters a biotech company can continue operating at its current burn rate before running out of cash. Most pre-revenue biotech companies fund operations through equity financing, so short runway often precedes dilutive stock offerings.
How is burn rate calculated?
Quarterly burn rate is calculated from 10-Q filings as the average quarterly net cash used in operating activities. We use the most recent filing available, typically within 45 days of quarter-end.
What does dilution risk mean for biotech investors?
When a biotech company's cash runway drops below 2 quarters, they typically need to raise capital through secondary offerings or ATM programs, which dilute existing shareholders. Monitoring runway helps you anticipate these events before they're announced.
How often is runway data updated?
Runway data updates quarterly when companies file 10-Q reports with the SEC. We also incorporate 8-K filings that disclose new financing events, and management guidance from earnings calls about expected runway.
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →